Novartis Ag

Other

Irm LLC

Carna Biosciences, Inc.

Sharp Kabushiki Kaisha Corporation

Takahiro Miyake

Keiichi Masuya

Osamu Ohmori

Eiji Kawahara

Ichiro Umemura

Carlos Garcia-Echeverria

Takanori Kanazawa

Naoko Matsuura

Nathanael Schiander Gray

Yukio Kurata

Donald Karanewsky

Yoshio Yoshida

Muneto Mogi

Qiong Zhang

Yongqin Wan

Qiang Ding

Keiji Sakai

Toshio Kawanami

Masaaki Sawa

Ruo W Steensma

Hidetomo Imase

Kayo Yasoshima

Ken Yamada

Toshio Ishikawa

Genji Iwasaki

Jiqing Jiang

Osamu Irie

Tokiko Asami

Takayuki Irie

Naoki Teno

Greg Chopiuk

Takao Kiyoi

Hongbo Qin

Yuko Asamitsu

Wataru Kawahata

Johannes Roesel

Yuki Iwaki

The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein

Triazine derivative

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP. 

Organic compounds

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Pyrimidine derivatives

Novel pyrimidine derivatives of formula I to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumors. 

Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors

Growing community of inventors

Tsukuba, Japan

Takahiro Miyake